Drug safety awareness in New Zealand: Public knowledge and preferred sources for information

Journal of Primary Health Care

Volumn 4, Issue 4, 2012, Pages 288-293

  Brounéus, Fredrik ^a   Macleod, Gregory ^a   Maclennan, Karyn ^a   Parkin, Lianne ^a   Paul, Charlotte ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Consumer health information; Drug safety; Medicine information; Patient education

Indexed keywords

EID: 84870955948     PISSN: 11726164     EISSN: 11726156     Source Type: Journal    
DOI: 10.1071/hc12288     Document Type: Article

References (30)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000; 356: 1255-59.
2. Ferner, RE, Aronson JK. Communication information about drug safety. BMJ. 2006; 333: 143-5.
3. Pouyanne P, Haramburu, Imbs JL, Begaud B for the French Pharmacovigilance Centres. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036.
4. Jha AK, Prasopa-Plaizier N, Larizgoitia I, Bates DW, Research Priority Setting Working Group for the WHO World Alliance for Patient Safety. Patient safety research: an overview of the global evidence. Qual Saf Health Care. 2010; 19: 42-47.
5. Desplenter F, Simoens S, Laekeman G. The impact of inform-ing psychiatric patients about their medication: a systematic review. Pharm World Sci. 2006; 28: 329-341.
6. Yilmaz MB, Pinar M, Naharci I, Demirkan B, Baysan O, Yoku-soglu M, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005; 19: 437-40.
7. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999; 47: 555-567.
8. Nair K, Dolovich L, Cassels A, McCormack J, Levine M, Gray J, Mann K, Burns S. What patients want to know about their medications. Focus group study of patient and clinician per-spectives. Can Fam Physician. 2002; 48: 104-10.
9. Ziegler DK, Mosier MC, Buenaver M, Okuyemi K. How much information about adverse effects of medication do patients want from physicians? Arch Int Med. 2001; 161: 706-13.
10. Berry DC, Michas IC, Gillie T, Forster M. What do patients want to know about their medicines, and what do doctors want to tell them? A comparative study. Psychol Health. 1997; 12: 467-480.
11. Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010; 33: 1065-79.
12. Uppsala Monitoring Centre. Dialogue in pharmacovigilance-more effective communication. Uppsala, Sweden: Uppsala Monitoring Centre; 2002.
13. Eagle L, Reid J, Hawkins J, Styles E. Breaking through the invisible barrier of low functional health literacy: implications for health communication. Studies in Communication Sciences 2005; 5: 29-56.
14. Hughes L, Whittlesea C, Luscombe D. Patients' knowledge and perceptions of the side-effects of OTC medication. J Clin Pharm Ther. 2002; 27: 243-8.
15. Wallace LS, Keenum AJ, Roskos SE, Blake GH, Colwell ST, Weiss BD. Suitability and readability of consumer medical information accompanying prescription medication samples. Patient Educ Couns. 2008; 70: 420-5.
16. Shiffman S, Gerlach KK, Sembower MA, Rohay JM. Consumer understanding of prescription drug information: an Illustra-tion using an antidepressant medication. Ann Pharmacother 2011; 45: 452-8.
17. Eggen A E. Patterns of medicine use in a general population (0-80 years). The influence of age, gender, diseases and place of residence on drug use in Norway. Pharmacoepidemiol Drug Saf. 1997; 6: 179-187.
18. Fernández-Liz E, Modamio P, Catalán A, Lastra CF, Rodríguez T, Mariño EL. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain. Br J Clin Pharmacol. 2008; 65: 407-17.
19. Dunning T, Manias E. Medication knowledge and self-man-agement by people with Type 2 diabetes. Aust J Adv Nurs. 2005; 23: 7-14.
20. Ascione FJ, Kirscht JP, Shimp LA. An assessment of different components of patient medication knowledge. Med Care. 1986; 24: 1018-1028.
21. Danesh-Meyer HV, Deva NC, Slight C, Tan YW, Tarr K, Carroll SC, et al. What do people with glaucoma know about their con-dition? A comparative cross-sectional incidence and prevalence survey. Clin Experiment Ophthalmol. 2008; 36: 13-8.
22. Sepucha KR, Fagerlin A, Couper MP, Levin CA, Singer E, Zikmund-Fisher BJ. How does feeling informed relate to being informed? The DECISIONS survey. Med Decis Making 2010; 30(5 Suppl): 77S-84S.
23. Cutilli CC. Seeking health information: what sources do your patients use? Orthop Nurs. 2010; 29: 214-219.
24. Luk A, Tasker N, Raynor DK, Aslani P. Written medicine information from English-speaking countries-how does it compare? Ann Pharmacother. 2010; 44: 285-94.
25. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. New Zealand Regulatory Guidelines for Medicines, Part D, Edition 6. 13, March 2011.
26. Abel GA, Neufeld EJ, Sorel M, Weeks JC. Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims. J Thromb Haemost. 2008; 6: 1680-4.
27. Macias W, Pashupati K, Lewis LS. A wonderful life or diarrhea and dry mouth? Policy issues of direct-to-consumer drug advertising on television. Health Commun. 2007; 22: 241-52.
28. Deshpande A, Menon A, Perri M, Zinkhan G. Direct-tocon-sumer advertising and its utility in health care decision making: a consumer perspective. J Health Commun. 2004; 9: 499-513.
29. Dens N, Eagle LC, De Pelsmacker P. Attitudes and self-re-ported behavior of patients, doctors, and pharmacists in New Zealand and Belgium toward direct-to-consumer advertising of medication. Health Commun 2008; 23: 45-61.
30. Brounéus F, MacLennan K, Parkin L, Paul C. Communicating drug safety information to health care professionals and the public-results from a survey by the University of Otago Pharmacovigilance Research Team. University of Otago report. 2011.